INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Oct 27, 2014 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 125,198 | $402.69 | 160,469 |
Nov 23, 2012 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 127,417 | $175.00 | 207,333 |
Dec 13, 2013 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 127,500 | -- | 127,500 |
Mar 09, 2020 |
Ten Percent Owner
Trans History: 555
|
Ten Percent Owner | Form 4 | Open market or private sale of non-derivative or derivative security | 128,914 | $489.65 | 20,421,899 |
Dec 12, 2018 |
Director, President & CEO
Trans History: 427
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 129,013 | -- | 129,013 |
Dec 12, 2018 |
Director, President and CSO
Trans History: 673
|
Director, President and CSO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 129,013 | -- | 129,013 |
Feb 15, 2012 |
Director, EVP CSO President Regeneron Re
Trans History: 673
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 129,902 | $8.50 | 962,943 |
Feb 15, 2012 |
Director, EVP CSO President Regeneron Re
Trans History: 673
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 129,902 | -- | 3,430 |
Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 673
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 129,902 | -- | 129,902 |
Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 673
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 130,714 | $483.25 | 750,224 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.